Market research
FATE Fate Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 279M
- P/E ratio
- Not available
- Analyst target
- 5.7444
- Dividend yield
- Not available
- Beta
- 2.55
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US31189P1021
- Market cap
- 279M
- P/E ratio
- Not available
- Analyst target
- 5.7444
- Dividend yield
- Not available
- Beta
- 2.55
About
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the FATE discussion.
5 years, 4 months ago
Fate Therapeutics, Inc is currently in a long term uptrend where the price is trading 8.9% above its 200 day moving average.
From a valuation standpoint, the stock is 83.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 219.3.
Fate Therapeutics, Inc's total revenue rose by 467.3% to $16M since the same quarter in the previous year.
Its net income has dropped by 87.7% to $-53M since the same quarter in the previous year.
Finally, its free cash flow grew by 18.4% to $-23M since the same quarter in the previous year.
Based on the above factors, Fate Therapeutics, Inc gets an overall score of 4/5.